Mexico Diabetes Drugs Market Size (2024 - 2029)

The Mexico Diabetes Drugs Market is projected to experience growth over the forecast period, driven by the increasing prevalence of diabetes, particularly Type 2, which has become a significant healthcare challenge in the country. Factors such as obesity, sedentary lifestyles, and genetic predisposition contribute to the rising incidence of diabetes, thereby influencing the market's expansion. The market's growth is further supported by the high number of adults affected by diabetes and the associated health expenditures, which highlight the urgent need for effective diabetes management solutions.

Market Size of Mexico Diabetes Drugs Industry

Mexico Diabetes Drugs Market Summary
Study Period 2018 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 2.04 Billion
Market Size (2029) USD 2.39 Billion
CAGR (2024 - 2029) 3.30 %

Major Players

Mexico Diabetes Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order

Mexico Diabetes Drugs Market Analysis

The Mexico Diabetes Drugs Market size is estimated at USD 2.04 billion in 2024, and is expected to reach USD 2.39 billion by 2029, growing at a CAGR of 3.30% during the forecast period (2024-2029).

In Mexico, diabetes, especially Type 2, became a healthcare burden as it is the primary cause of death among women and the secondary cause of death among men. Obesity, sedentarism, bad eating habits, genetics, family background, and age are among the factors that lead to developing diabetes. Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

In 2022, the International Diabetes Federation estimated that approximately 14.1 million adults in Mexico were affected by diabetes. This accounts for nearly 17 percent of the entire adult population in the country, which equated to over 83 million individuals during that year. Overweight is identified as one of the risk factors associated with this disease, and it is projected that the proportion of overweight individuals in Mexico will continue to rise in the coming years.

there are 11 million adults in the country have Impaired Glucose tolerance (IGT), which places them at high risk of developing type 2 diabetes. Diabetes-related health expenditure in Mexico has reached USD 20 billion, putting it in the top ten countries or territories with the highest total health expenditure. Under half (47.5%) of people living with diabetes in the country are undiagnosed.

When diabetes is undetected or inadequately treated, people with diabetes are at risk of serious and life-threatening complications, such as heart attack, stroke, kidney failure, blindness, and lower-limb amputation. These result in reduced quality of life and higher healthcare costs and lead to a greater need for access to care.

Mexico Diabetes Drugs Industry Segmentation

Diabetes Drugs are used to manage diabetes mellitus by lowering the glucose level in the blood. The Mexico Diabetes Drugs Market is segmented into drugs, oral anti-diabetic drugs, non-insulin injectable drugs and combination drugs. The report offers the value (in USD) and volume (in units) for the above segments.

Insulins
Basal or Long Acting Insulins
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast Acting Insulins
NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
Traditional Human Insulins
Novolin/Actrapid/Insulatard
Humulin
Insuman
Biosimilar Insulins
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Oral Anti-diabetic drugs
Biguanides
Metformin
Alpha-Glucosidase Inhibitors
Alpha-Glucosidase Inhibitors
Dopamine D2 receptor agonist
Bromocriptin
SGLT-2 inhibitors
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
DPP-4 inhibitors
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina(Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas
Sulfonylureas
Meglitinides
Meglitinides
Non-Insulin Injectable drugs
GLP-1 receptor agonists
Victoza (Liraglutide)
Byetta (Exenatide)
Bydureon (Exenatide)
Trulicity (Dulaglutide)
Lyxumia (Lixisenatide)
Amylin Analogue
Symlin (Pramlintide)
Combination drugs
Insulin combinations
NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Oral Combinations
Janumet (Sitagliptin and Metformin)
Need A Different Region Or Segment?
Customize Now

Mexico Diabetes Drugs Market Size Summary

The Mexico Diabetes Drugs Market is poised for growth, driven by the increasing prevalence of diabetes, particularly Type 2, which has become a significant healthcare challenge in the country. Factors such as obesity, sedentary lifestyles, poor dietary habits, and genetic predispositions contribute to the rising incidence of diabetes. The market is expected to expand as the demand for diabetes management solutions grows, with oral anti-diabetic drugs playing a crucial role due to their efficacy, safety, and cost-effectiveness. These medications are essential for controlling blood glucose levels and preventing complications, making them a preferred choice over insulin for many patients. The Mexican government's initiatives, including community-based and national health insurance programs, aim to improve access to healthcare services, further supporting market growth.

The market landscape is moderately consolidated, with major pharmaceutical companies like Eli Lilly, Sanofi, Novo Nordisk, and AstraZeneca leading the charge. These companies are actively engaged in strategic mergers and acquisitions to enhance their market presence and drive innovation. Technological advancements, particularly in SGLT-2 inhibitors, are contributing to the development of new treatment options, improving patient outcomes, and expanding market opportunities. The integration of digital platforms, such as Roche's mu Sugr, underscores the industry's shift towards comprehensive diabetes management solutions. As awareness of diabetes increases and new products are introduced, the market is expected to continue its upward trajectory, addressing the growing healthcare needs of the Mexican population.

Explore More

Mexico Diabetes Drugs Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

    3. 1.3 Market Restraints

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 Insulins

      1. 2.1.1 Basal or Long Acting Insulins

        1. 2.1.1.1 Lantus (Insulin Glargine)

        2. 2.1.1.2 Levemir (Insulin Detemir)

        3. 2.1.1.3 Toujeo (Insulin Glargine)

        4. 2.1.1.4 Tresiba (Insulin Degludec)

        5. 2.1.1.5 Basaglar (Insulin Glargine)

      2. 2.1.2 Bolus or Fast Acting Insulins

        1. 2.1.2.1 NovoRapid/Novolog (Insulin Aspart)

        2. 2.1.2.2 Humalog (Insulin Lispro)

        3. 2.1.2.3 Apidra (Insulin Glulisine)

      3. 2.1.3 Traditional Human Insulins

        1. 2.1.3.1 Novolin/Actrapid/Insulatard

        2. 2.1.3.2 Humulin

        3. 2.1.3.3 Insuman

      4. 2.1.4 Biosimilar Insulins

        1. 2.1.4.1 Insulin Glargine Biosimilars

        2. 2.1.4.2 Human Insulin Biosimilars

    2. 2.2 Oral Anti-diabetic drugs

      1. 2.2.1 Biguanides

        1. 2.2.1.1 Metformin

      2. 2.2.2 Alpha-Glucosidase Inhibitors

        1. 2.2.2.1 Alpha-Glucosidase Inhibitors

      3. 2.2.3 Dopamine D2 receptor agonist

        1. 2.2.3.1 Bromocriptin

      4. 2.2.4 SGLT-2 inhibitors

        1. 2.2.4.1 Invokana (Canagliflozin)

        2. 2.2.4.2 Jardiance (Empagliflozin)

        3. 2.2.4.3 Farxiga/Forxiga (Dapagliflozin)

        4. 2.2.4.4 Suglat (Ipragliflozin)

      5. 2.2.5 DPP-4 inhibitors

        1. 2.2.5.1 Onglyza (Saxagliptin)

        2. 2.2.5.2 Tradjenta (Linagliptin)

        3. 2.2.5.3 Vipidia/Nesina(Alogliptin)

        4. 2.2.5.4 Galvus (Vildagliptin)

      6. 2.2.6 Sulfonylureas

        1. 2.2.6.1 Sulfonylureas

      7. 2.2.7 Meglitinides

        1. 2.2.7.1 Meglitinides

    3. 2.3 Non-Insulin Injectable drugs

      1. 2.3.1 GLP-1 receptor agonists

        1. 2.3.1.1 Victoza (Liraglutide)

        2. 2.3.1.2 Byetta (Exenatide)

        3. 2.3.1.3 Bydureon (Exenatide)

        4. 2.3.1.4 Trulicity (Dulaglutide)

        5. 2.3.1.5 Lyxumia (Lixisenatide)

      2. 2.3.2 Amylin Analogue

        1. 2.3.2.1 Symlin (Pramlintide)

    4. 2.4 Combination drugs

      1. 2.4.1 Insulin combinations

        1. 2.4.1.1 NovoMix (Biphasic Insulin Aspart)

        2. 2.4.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)

        3. 2.4.1.3 Xultophy (Insulin Degludec and Liraglutide)

      2. 2.4.2 Oral Combinations

        1. 2.4.2.1 Janumet (Sitagliptin and Metformin)

Mexico Diabetes Drugs Market Size FAQs

The Mexico Diabetes Drugs Market size is expected to reach USD 2.04 billion in 2024 and grow at a CAGR of 3.30% to reach USD 2.39 billion by 2029.

In 2024, the Mexico Diabetes Drugs Market size is expected to reach USD 2.04 billion.

Mexico Diabetes Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)